Cargando…

Role of B7 family members in glioma: Promising new targets for tumor immunotherapy

Glioma, is a representative type of intracranial tumor among adults, usually has a weak prognosis and limited treatment options. Traditional therapies, including surgery, chemotherapy, and radiotherapy, have had little impact on patient survival time. Immunotherapies designed to target the programme...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yan, Li, Mengxi, Wang, Gang, Wu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890054/
https://www.ncbi.nlm.nih.gov/pubmed/36741734
http://dx.doi.org/10.3389/fonc.2022.1091383
_version_ 1784880870960660480
author Wang, Yan
Li, Mengxi
Wang, Gang
Wu, Hui
author_facet Wang, Yan
Li, Mengxi
Wang, Gang
Wu, Hui
author_sort Wang, Yan
collection PubMed
description Glioma, is a representative type of intracranial tumor among adults, usually has a weak prognosis and limited treatment options. Traditional therapies, including surgery, chemotherapy, and radiotherapy, have had little impact on patient survival time. Immunotherapies designed to target the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) signaling pathway have successfully treated various human cancers, informing the development of similar therapies for glioma. However, anti-PD-L1 response rates remain limited in glioma patients. Thus, exploring novel checkpoints targeting additional immunomodulatory pathways for activating durable antitumor immune responses and improving glioma outcomes is needed. Researchers have identified other B7 family checkpoint molecules, including PD-L2, B7-H2, B7-H3, B7-H4, and B7-H6. The current review article evaluates the expression of all 10 reported members of the B7 family in human glioma using The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) data, as well as summarizes studies evaluating the clinical meanings and functions of B7 family molecules in gliomas. B7 family checkpoints may contribute to different immunotherapeutic management options for glioma patients.
format Online
Article
Text
id pubmed-9890054
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98900542023-02-02 Role of B7 family members in glioma: Promising new targets for tumor immunotherapy Wang, Yan Li, Mengxi Wang, Gang Wu, Hui Front Oncol Oncology Glioma, is a representative type of intracranial tumor among adults, usually has a weak prognosis and limited treatment options. Traditional therapies, including surgery, chemotherapy, and radiotherapy, have had little impact on patient survival time. Immunotherapies designed to target the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) signaling pathway have successfully treated various human cancers, informing the development of similar therapies for glioma. However, anti-PD-L1 response rates remain limited in glioma patients. Thus, exploring novel checkpoints targeting additional immunomodulatory pathways for activating durable antitumor immune responses and improving glioma outcomes is needed. Researchers have identified other B7 family checkpoint molecules, including PD-L2, B7-H2, B7-H3, B7-H4, and B7-H6. The current review article evaluates the expression of all 10 reported members of the B7 family in human glioma using The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) data, as well as summarizes studies evaluating the clinical meanings and functions of B7 family molecules in gliomas. B7 family checkpoints may contribute to different immunotherapeutic management options for glioma patients. Frontiers Media S.A. 2023-01-18 /pmc/articles/PMC9890054/ /pubmed/36741734 http://dx.doi.org/10.3389/fonc.2022.1091383 Text en Copyright © 2023 Wang, Li, Wang and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Yan
Li, Mengxi
Wang, Gang
Wu, Hui
Role of B7 family members in glioma: Promising new targets for tumor immunotherapy
title Role of B7 family members in glioma: Promising new targets for tumor immunotherapy
title_full Role of B7 family members in glioma: Promising new targets for tumor immunotherapy
title_fullStr Role of B7 family members in glioma: Promising new targets for tumor immunotherapy
title_full_unstemmed Role of B7 family members in glioma: Promising new targets for tumor immunotherapy
title_short Role of B7 family members in glioma: Promising new targets for tumor immunotherapy
title_sort role of b7 family members in glioma: promising new targets for tumor immunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890054/
https://www.ncbi.nlm.nih.gov/pubmed/36741734
http://dx.doi.org/10.3389/fonc.2022.1091383
work_keys_str_mv AT wangyan roleofb7familymembersingliomapromisingnewtargetsfortumorimmunotherapy
AT limengxi roleofb7familymembersingliomapromisingnewtargetsfortumorimmunotherapy
AT wanggang roleofb7familymembersingliomapromisingnewtargetsfortumorimmunotherapy
AT wuhui roleofb7familymembersingliomapromisingnewtargetsfortumorimmunotherapy